NasdaqGS - Nasdaq Real Time Price USD

United Therapeutics Corporation (UTHR)

Compare

367.36

+3.03

(+0.83%)

At close: November 21 at 4:00 PM EST

367.50

+0.14

(+0.04%)

Pre-Market: 7:14 AM EST

Report Name

Direction

Rating

Price Target

Morningstar ?Analyst Report ?21 days ago

United Therapeutics Corporation: United Therapeutics Earnings: Strong Demand for Tyvaso DPI, but Branded Competition Poses Challenges

Direction

Rating

Price Target

Argus ?Analyst Report ?22 days ago

United Therapeutics Corporation: Raising target price to $400

Direction

Rating

Price Target

Argus ?Market Summary ?22 days ago

Market Digest: ADP, LLY, MCD, UTHR, WM, SMCI, HCA, QRVO, SNAP

Direction -

Rating -

Price Target -

Argus ?Thematic Portfolio ?last month

The Argus Mid-Cap Model Portfolio

Direction -

Rating -

Price Target -

Argus ?Market Outlook ?2 months ago

Daily Spotlight: Not All Sectors Are Equal

Direction -

Rating -

Price Target -

Argus ?Stock Picks ?2 months ago

Weekly Stock List: Focus List Changes

Direction -

Rating -

Price Target -

Argus ?Portfolio Ideas ?2 months ago

Rate-Cut Rotation

Direction -

Rating -

Price Target -

Morningstar ?Analyst Report ?2 months ago

United Therapeutics Corporation: United Therapeutics Earnings: Tyvaso DPI Sees Strong Demand, but Headwinds From Branded Competition

Direction

Rating

Price Target

Argus ?Analyst Report ?3 months ago

United Therapeutics Corporation: Raising target price to $360

Direction

Rating

Price Target

Argus ?Market Summary ?3 months ago

Market Digest: APD, THRM, CTSH, HES, MGM, TMUS, SYK, UTHR, WEN, APTV

Direction -

Rating -

Price Target -

Argus ?Analyst Report ?4 months ago

United Therapeutics Corporation: Raising target price to $350

Direction

Rating

Price Target

Argus ?Market Summary ?4 months ago

Market Digest: STZ, UTHR, NET

Direction -

Rating -

Price Target -

Morningstar ?Analyst Report ?6 months ago

United Therapeutics Corporation: United Therapeutics Earnings: Strong Uptake of Tyvaso DPI Drives Sales Amid Branded Competition

Direction

Rating

Price Target

Argus ?Analyst Report ?7 months ago

United Therapeutics Corporation: BUY on growth of Tyvaso DPI and pipeline advances

Direction

Rating

Price Target

Argus ?Market Summary ?7 months ago

Market Digest: BJ, LH, MCD, MDU, ES, UTHR

Direction -

Rating -

Price Target -

Morningstar ?Analyst Report ?8 months ago

United Therapeutics Corporation: United Therapeutics Earnings: Strong Demand for Tyvaso DPI Drives Growth; Shares Fairly Valued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?8 months ago

United Therapeutics Corporation: No-Moat United Therapeutics Faces Pressure Amid Patent Expirations and Branded Competition

Direction

Rating

Price Target

Argus ?Analyst Report ?11 months ago

United Therapeutics Corporation: Reiterating BUY and $280 target

Direction

Rating

Price Target

Argus ?Market Update ?11 months ago

Market Update: UAA, APD, UTHR, DELL

Direction -

Rating -

Price Target -

Morningstar ?Analyst Report ?last year

United Therapeutics Corporation: United Therapeutics Earnings: Demand for Tyvaso DPI Drives Strong Sales; Shares Fairly Valued

Direction

Rating

Price Target

Argus ?Market Update ?last year

Market Update: EQIX, HPQ, UTHR, VRTX, AVGO, KHC

Direction -

Rating -

Price Target -

Argus ?Market Update ?last year

Market Update: AVB, EQIX, HPQ, UTHR, VRTX, KHC

Direction -

Rating -

Price Target -

LQDA Liquidia Corporation

10.15

+0.30%

ARGX argenx SE

596.74

+0.83%

ALNY Alnylam Pharmaceuticals, Inc.

246.80

-0.80%

HALO Halozyme Therapeutics, Inc.

45.70

-0.13%

EXEL Exelixis, Inc.

34.83

+0.52%

MNKD MannKind Corporation

6.90

+0.29%

INCY Incyte Corporation

70.39

-0.93%

TECH Bio-Techne Corporation

71.05

+3.39%

CORT Corcept Therapeutics Incorporated

55.92

-0.30%

ASND Ascendis Pharma A/S

122.64

-1.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

United Therapeutics Corporation (UTHR)

Research Reports: UTHR

United Therapeutics Corporation: United Therapeutics Earnings: Strong Demand for Tyvaso DPI, but Branded Competition Poses Challenges

United Therapeutics Corporation: Raising target price to $400

Market Digest: ADP, LLY, MCD, UTHR, WM, SMCI, HCA, QRVO, SNAP

The Argus Mid-Cap Model Portfolio

Daily Spotlight: Not All Sectors Are Equal

Weekly Stock List: Focus List Changes

Rate-Cut Rotation

United Therapeutics Corporation: United Therapeutics Earnings: Tyvaso DPI Sees Strong Demand, but Headwinds From Branded Competition

United Therapeutics Corporation: Raising target price to $360

Market Digest: APD, THRM, CTSH, HES, MGM, TMUS, SYK, UTHR, WEN, APTV

United Therapeutics Corporation: Raising target price to $350

Market Digest: STZ, UTHR, NET

United Therapeutics Corporation: United Therapeutics Earnings: Strong Uptake of Tyvaso DPI Drives Sales Amid Branded Competition

United Therapeutics Corporation: BUY on growth of Tyvaso DPI and pipeline advances

Market Digest: BJ, LH, MCD, MDU, ES, UTHR

United Therapeutics Corporation: United Therapeutics Earnings: Strong Demand for Tyvaso DPI Drives Growth; Shares Fairly Valued

United Therapeutics Corporation: No-Moat United Therapeutics Faces Pressure Amid Patent Expirations and Branded Competition

United Therapeutics Corporation: Reiterating BUY and $280 target

Market Update: UAA, APD, UTHR, DELL

United Therapeutics Corporation: United Therapeutics Earnings: Demand for Tyvaso DPI Drives Strong Sales; Shares Fairly Valued

Market Update: EQIX, HPQ, UTHR, VRTX, AVGO, KHC

Market Update: AVB, EQIX, HPQ, UTHR, VRTX, KHC

Related Tickers